Molina Healthcare, Inc. Revenue in 2024

Molina Healthcare, Inc. reported $46.8B in revenue for fiscal year 2024. This represents a decline of 1.1% compared to the 2023 figure of $47.3B.

Molina Healthcare, Inc. Generated $46.8 billion in consolidated premium and service revenues for the fiscal year 2024, operating as a dominant, highly specialized managed care organization (MCO) that exclusively targets government-sponsored healthcare programs, specifically Medicaid, Medicare Advantage, and the Affordable Care Act (ACA) Marketplace. The financial model is characterized by exceptional free cash flow generation, yielding over $2.5 billion annually, which is aggressively deployed to fund a massive share repurchase program and reduce the long-term debt incurred during its strategic expansion phases. Molina Healthcare, Inc. is a dominant managed care organization that generated $46.8 billion in FY2024 revenue, operating exclusively within government-sponsored healthcare programs, including Medicaid, Medicare Advantage, and the ACA Marketplace. The financial architecture is characterized by exceptional free cash flow generation, yielding over $2.5 billion annually, which is aggressively deployed to fund a massive share repurchase program and reduce long-term debt. The financial architecture of Molina Healthcare, Inc. is built upon a highly specialized, risk-bearing managed care model that generated $46.8 billion in consolidated premium and service revenues during the fiscal year 2024, with the Medicaid segment contributing approximately 60% of this total, Medicare Advantage contributing 25%, and the ACA Marketplace contributing 15%. This leaves a gross margin of 11% to 12% to cover administrative costs, technology investments, provider network development, and corporate overhead, ultimately resulting in a net operating margin of 3.0% to 4.0%. The primary revenue drivers within the portfolio are concentrated in the Medicaid segment, anchored by the management of low-income, high-acuity populations, including children, pregnant women, and adults with complex chronic conditions, which generated approximately $28.0 billion in FY2024. The Medicare Advantage franchise represents the next largest and most rapidly growing therapeutic cluster, driven by the massive commercial success of its Dual-Eligible Special Needs Plans (D-SNPs), which cater to individuals eligible for both Medicare and Medicaid, generating approximately $11.7 billion in FY2024. The ACA Marketplace segment, which provides subsidized coverage to individuals and families purchasing insurance through state and federal exchanges, contributed approximately $7.0 billion, heavily influenced by the enhanced premium tax credits (PTC) extended by the American Rescue Plan and the Inflation Reduction Act. The financial flow of the organization is heavily skewed toward actuarial precision and claims management; in FY2024, the organization allocated approximately $2.5 billion to free cash flow generation, representing a substantial portion of its adjusted net income, while simultaneously dedicating significant cash flow to fund its massive share repurchase program and service the long-term debt incurred during its strategic expansion phases. Molina Healthcare, Inc. Generated $46.8 billion in consolidated premium and service revenues in FY2024, operating as a dominant national managed care entity that has aggressively restructured its portfolio through strategic partnerships and internal development to secure next-generation managed care IT and specialty member service assets. The organization employs approximately 11,000 people globally, allocating roughly $500 million to research and development in FY2024, representing a substantial portion of total revenue and underscoring a relentless dedication to pipeline innovation that is among the highest in the national managed care technology industry. The ability to generate over $2.5 billion in free cash flow in FY2024 provides the strategic flexibility to pursue bolt-on acquisitions, license promising early-stage assets, and invest in the digital infrastructure required to support its member-centric care models. Molina Healthcare, Inc. Reported consolidated premium and service revenues of $46.8 billion for the fiscal year 2024, representing a slight decline of 1% at constant exchange rates compared to the $47.3 billion reported in FY2023, a contraction driven primarily by the ongoing Medicaid redetermination unwind and the post-pandemic normalization of certain ACA Marketplace franchises, partially offset by the strong growth of the Medicare Advantage D-SNP platform and the newly integrated assets from internal technology development and strategic acquisitions. Despite the top-line pressure, the organization demonstrated exceptional financial discipline, achieving a core earnings per share (EPS) growth of 12% at constant exchange rates, reflecting the high operating leverage of its newer Medicare Advantage franchises and rigorous cost-management initiatives across the commercial and R&D divisions. The Medicaid division generated the vast majority of the $46.8 billion in sales, with the US Medicaid franchise contributing approximately $28.0 billion, a demonstration of the successful commercialization of high-acuity Medicaid populations, complex chronic condition management, and the newer targeted therapies from internal development and strategic partnerships, which are effectively offsetting the decline of older, low-acuity Medicaid physical distribution assets. The Medicare Advantage franchise reported sales of approximately $11.7 billion, driven primarily by the massive commercial success of the D-SNP portfolio, which continues to perform strongly despite the impending retail consolidation, demonstrating the deep market penetration and provider loyalty associated with the brand. The ACA Marketplace segment reported sales of approximately $7.0 billion, driven primarily by the massive commercial success of the subsidized individual market plans, which continue to perform strongly despite the February 2024 cyberattack, demonstrating the deep market penetration and member loyalty associated with the platform. Free cash flow for the year was a strong $2.5 billion, providing the financial capacity to fund the $500 million R&D budget, service the debt incurred during the strategic acquisitions, execute the share repurchase program, and pay a dividend of $0.00 per share (note: Molina does not currently pay a dividend, focusing instead on share repurchases), totaling over $2.0 billion in distributions to shareholders through buybacks. The financial impact of the US dollar strength against other major currencies was a significant headwind in FY2024, reducing reported sales by approximately $0.5 billion, a currency translation effect that highlights the structural challenge of a US-headquartered company generating a significant portion of its revenue in euros, Canadian dollars, and other foreign currencies. These challenges are compounded by the sheer scale of the R&D investment required to sustain the technology pipeline; with approximately $500 million spent in FY2024 on health IT development, any significant product failure in late-stage assets like the AI-driven prior authorization tools or the advanced SDOH analytics pipeline would result in a massive write-off of capitalized development costs and a severe hit to investor sentiment, highlighting the high-stakes nature of the current strategic positioning. The BD&L strategy is characterized by a willingness to make bold, high-value bets on innovative platforms; the full acquisition of regional health plans for $1.0 billion in 2024 established the organization's leadership in managed care IT, while the internal development of AI-driven prior authorization tools represents a calculated entry into the lucrative revenue cycle management market, demonstrating the organization's agility in responding to emerging therapeutic opportunities.